roseomonas mucosa

**Roseomonas mucosa** is a topical live biotherapeutic product based on a commensal Gram-negative skin bacterium isolated from healthy volunteers and developed primarily for **atopic dermatitis**. In NIH/NIAID-led preclinical and clinical studies, live healthy-volunteer strains of *R. mucosa* reduced *Staphylococcus aureus* burden, improved barrier function and eczema severity, and showed persistence on skin after treatment cessation. Mechanistically, the therapeutic effect appears to be mediated mainly through production of beneficial bacterial lipids, including glycerophospholipid and sphingolipid-related mediators, with downstream promotion of epithelial repair pathways involving **TNFR2**, IL-8/CXCR2 signaling, cholinergic signaling via nicotinic acetylcholine receptors, and effects linked to TLR5/flagellin biology. The initial NIH Phase 1/2 BACTERiAD study was followed by development as **FB-401** under license to Forte Biosciences; however, a later placebo-controlled Phase 2b program did not meet its primary commercial endpoints, although post hoc analyses suggested modest benefit in protocol completers.

Other names

Roseomonas mucosaR. mucosaRoseomonas mucosa from healthy volunteersRmHVRSM2015RSM-2015RSM 2015